Genmab to Participate in Upcoming Investor Conferences

About this update from Genmab A/s

[{"type":"image","alt":"Genmab A/S","displaySize":"","headline":null,"caption":"Genmab A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":275,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/c0cd563151331363bc069dc3ced1531d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3fXMaEmkURmdIw8oGLJV.g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c0cd563151331363bc069dc3ced1531d","width":275,"height":85}},"lazy":false},{"type":"text","content":"Media ReleaseCOPENHAGEN, Denmark; February 25, 2026Genmab A/S (Nasdaq: GMAB) announced today that members of its Executive Committee will participate in fireside chats at the following investor conferences in March 2026: ","length":224,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"TD Cowen 46th Annual Healthcare Conference in Boston on March 3, 2026, 9:10 AM EST (3:10 PM CET)","length":96,"tagName":"p"}]},{"val":[{"type":"text","content":"Leerink Global Healthcare Conference in Miami on March 10, 2026, 8:40 AM EDT (1:40 PM CET)","length":90,"tagName":"p"}]},{"val":[{"type":"text","content":"Barclays 28th Annual Global Healthcare Conference in Miami on March 11, 2026, 1:30 PM EDT (6:30 PM CET)","length":103,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":289,"olType":false},{"type":"text","content":"The live and archived webcast of the presentations will be available on Genmab’s website at https://ir.genmab.com/events-presentations.","length":140,"tagName":"p"},{"type":"text","content":"About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For more than 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody medicines®.","length":762,"tagName":"p"},{"type":"text","c...

More updates from Genmab A/s